Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alfacell Corporation
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
April 18th, 2008
Alfacell Corporation (NASDAQ:ACEL) announced that it has confirmed that 316 evaluable events (patient deaths) have occurred in the confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), for the treatment of patients with unresectable malignant mesothelioma (UMM). In accordance with the statistical plan for the trial, the company has begun the process necessary to conduct the formal statistical analyses required to complete the final sections of the ONCONASE rolling New Drug Application (NDA). The trial was designed to show a statistically significant improvement in overall survival for UMM patients who were treated with a combination of...
Source: Health Business Week (2008-04-18)
|
